

## Evkeeza™ (evinacumab) – New orphan drug approval

- On February 11, 2021, [Regeneron announced the FDA approval](#) of [Evkeeza \(evinacumab\)](#), as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
  - The safety and effectiveness of Evkeeza have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia.
  - The effects of Evkeeza on cardiovascular morbidity and mortality have not been determined.
- HoFH is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. HoFH occurs when two copies of the FH-causing genes are inherited, one from each parent, resulting in high levels of LDL-C. Patients with HoFH are at risk for premature atherosclerotic disease and cardiac events as early as their teenage years.
- Evkeeza is a first-in-class monoclonal antibody that binds to and blocks the function of angiotensin-like protein 3 (ANGPTL3). ANGPTL3 is a member of the angiotensin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism.
- The efficacy of Evkeeza was established in ELIPSE-HoFH, a double-blind, randomized, placebo-controlled study in 65 patients with HoFH. Patients were on a background of other lipid-lowering therapies, including maximally tolerated statins, [ezetimibe](#), PCSK9 inhibitor antibodies, [Juxtapid® \(lomitapide\)](#), and lipoprotein apheresis. The primary efficacy endpoint was percent change in LDL-C from baseline to week 24.
  - At week 24, the least squares mean treatment difference between Evkeeza and placebo in mean percent change in LDL-C from baseline was -49% (95% CI: -65, -33% p < 0.0001).
- Warnings and precautions for Evkeeza include serious hypersensitivity reactions and embryo-fetal toxicity.
- The most common adverse reactions (≥ 5%) with Evkeeza use were nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea.
- The recommended dose of Evkeeza is 15 mg/kg administered by intravenous (IV) infusion over 60 minutes once monthly (every 4 weeks).
  - LDL-C should be assessed when clinically appropriate. The LDL-lowering effect of Evkeeza may be measured as early as 2 weeks after initiation.
- The average Wholesale Acquisition Cost (WAC) per patient for Evkeeza will vary based on weight, and is expected to be approximately \$450,000 per year on average.

- Regeneron's launch plans for Evkeeza are pending. Evkeeza will be available as 345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) solutions in single-dose vials.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.